DWTX
Dogwood Therapeutics, Inc.
NASDAQ: DWTX · HEALTHCARE · BIOTECHNOLOGY
$1.43
+5.93% today
Updated 2026-04-30
Market cap
$46.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-7.13
Dividend yield
—
52W range
$1 – $10
Volume
0.1M
Dogwood Therapeutics, Inc. (DWTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | $12177.00 | — |
| Gross profit | — | — | — | — | — | — | $-12177.00 | — |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $854109.00 | $800620.00 | $194013.00 | $10.80M | $8.07M | $1.73M | $3.53M | $21.87M |
| SG&A | $1.11M | $1.38M | $9.81M | $4.85M | $4.25M | $3.72M | $8.70M | $6.10M |
| Operating income | $-1.96M | $-2.18M | $-10.01M | $-15.64M | $-12.32M | $-5.45M | $-12.23M | $-27.97M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-1.96M | $-2.18M | $-10.01M | $-15.64M | $-12.32M | $-5.45M | $-12.25M | $-27.97M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-1.96M | $-2.18M | $-10.01M | $-15.64M | $-12.32M | $-5.45M | $-12.26M | $-27.97M |
| Interest expense | $152103.00 | $295128.00 | $384222.00 | — | — | — | $92192.00 | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.11M | $-2.47M | $-10.35M | $-15.96M | $-12.25M | $-5.30M | $-12.35M | $-34.26M |
| Net income growth (YoY) | — | -17.0% | -318.3% | -54.3% | +23.3% | +56.8% | -133.2% | -177.4% |
| Profit margin | — | — | — | — | — | — | — | — |